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Abstract 
 
Importance: Female adolescents and young adults in the United States have high rates of 
unintended pregnancy and STI acquisition.  
 
Objective: Determine whether female adolescents and young adults who use long acting 
reversible contraceptives (LARCs) are less likely to use a hormonal contraceptive or copper IUD 
concurrently with a condom, also known as dual method use. As a result, they have a higher 
sexually transmitted infection (STI) incidence than those who use other short acting reversible 
contraceptives (SARCs). 
 
Data Source: Searches of PubMed, Cochrane, CINAHL, Embase, and ClinicalTrials.gov for 
relevant studies published from January 1, 1988 through April 5, 2018. 
 
Study Selection: English-language studies conducted in female adolescent and/or young adults 
comparing rates of dual method use and/or STI incidence between LARC and SARC users.    
 
Data Extraction and Syntheses: One investigator reviewed abstracts and full-text articles. 
Studies were unable to be pooled given the degree of clinical and methodological heterogeneity. 
 
Main Outcome and Measures: Dual method use and STI incidence. 
 
Results: The review included 5 studies – 4 prospective cohort studies and 1 cluster randomized 
trial. Strength of evidence for both outcomes was low given high risk of bias, lack of power, and 
indirectness of evidence. A large cohort study (N=1048) with moderate risk of bias and a small 
cohort study (N=399) with critical risk of bias found decreased dual method use among LARC 
users (RR 0.69 [95% CI 0.57 to 0.83]; RR 0.48 [95% CI 0.28 to 0.82], respectively). A cluster 
randomized trial (N=1500) with low risk of bias and a small cohort study (N=210) with critical 
risk of bias found no significant difference in dual method use (RR 0.98 [95% CI 0.75 to 1.29]; 
RR 0.99 [95% CI 0.78 to 1.26], respectively). There was no difference in STI incidence between 
female adolescent and young adult users of LARCs and SARCs.   
 
Conclusion: More high-quality studies are needed to strengthen the body of literature on the 
relationship of LARC uptake on dual method use and STI acquisition. Providers should continue 
to emphasize the need for both protection against pregnancy and STIs in adolescent and young 
women seeking contraception. 
 
 
 
 
1 
 
Introduction 
  
 Adolescents and young women (aged 15-24) have the highest risk of unintended 
pregnancy and sexually transmitted infections (STIs). While almost half (45%) of all pregnancies 
in the United States are unintended, this proportion increases to 75% among teenagers 15-19 
years old and 59% among young women 20-24 years old.1 The United States has one of the 
highest teen birth rates among industrialized countries.2 Pregnancy rates among adolescents 15-
19 years old dropped by 25% between 2007 and 2011, primarily a result of increased 
contraceptive use.2  However, teens still typically use less effective contraceptive methods such 
as condoms and have less consistent use than older persons. Of the estimated 19 million new 
cases of STIs in the United States, half occur among young people 15-24 years old.3 The rates of 
reported chlamydia, gonorrhea, and syphilis have increased between 2012-2016 in both 
adolescents and young adults.3 Thus, it is important that this population is offered appropriate 
contraception that is effective for the prevention of both pregnancy and STIs.  
Long Acting Reversible Contraceptives (LARCs) such as levonorgestrel-release 
intrauterine devices (IUDs), copper IUDs, and implants have higher effectiveness levels for 
preventing pregnancy as compared to short acting reversible contraceptives (SARCs) such as 
oral contraceptive pills (OCPs) and vaginal ring. The percentage of women who have an 
unintended pregnancy within the first year of typical use for LARCs range from 0.05% - 0.8%.2 
LARC use has been traditionally low in the United States and has gradually increased the past 
decade to 12.0% among women aged 15-44.4–6 Rates of use among female adolescents and 
young adults are 4.5% and 8.3%, respectively.6 The Centers for Disease Control and Prevention, 
American College of Obstetricians and Gynecologist, and the American Academy of Pediatrics 
all endorse the use of LARCs in adolescents and young women.7–9 
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There have been many initiatives to increase knowledge and use of LARCs among young 
women in United States, and LARC uptake is expected to continue to increase.10–14 While 
LARCs are effective at preventing unintended pregnancies, they offer no protection against STIs. 
Barrier methods such as male and female condoms, if used consistently and correctly, can 
provide good protection against STIs. However, condoms are not as effective as LARCs for 
pregnancy protection. The percentage of women who have an unintended pregnancy within the 
first year of typical use of condoms is 18-21%.2 Thus, use of a hormonal contraceptive or copper 
IUD concurrently with a condom, also known as dual method use, is a crucial health strategy for 
preventing both pregnancy and STIs among female adolescents and young women ages 15-24.  
Evidence on whether LARC use leads to lower levels of condom use among adolescents 
and young adults is conflicting.15–24 Many cross-sectional studies using data from national 
surveys show that dual method use is lower among LARC users than other contraceptive 
methods. However, these studies demonstrate an association, but not necessarily a causation. 
While there are randomized studies on LARCs and dual method use, a limited number are 
conducted in the adolescent and young adult age groups within the United States. In addition, it 
is uncertain whether decreased dual method use among female adolescents and young women 
results in higher rates of STI acquisition. Despite the potential implications on public health 
interventions, there has not been a systematic review of studies related to this topic. Thus, I 
conducted a systematic review to determine whether female adolescents and young adults who 
use LARCs are less likely to engage in dual method use and as a result have a higher STI 
incidence than those who use other SARCs.  
 
Methods  
 
Data Sources and Searches  
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With the assistance of a health sciences librarian, I developed a literature search strategy 
using medical subject headings and key words related to LARCs, IUDs, Implants, adolescents, 
young adults, STIs, condoms, and dual method use. Relevant articles were identified from 
searches conducted in PubMed, Cochrane, CINAHL, Embase, and ClinicalTrials.gov. The search 
was limited to English-language studies published from January 1, 1988 to April 5, 2018. The 
timeframe of 1988 was selected as it was when the copper IUD became available to the US 
market, which is the earliest date of availability among all currently FDA approved LARCs.25 No 
study design or country of study limits were imposed for the search. Electronic searches were 
identified through review of reference lists of included studies, background articles, and related 
systematic reviews and guidelines. The specific search strategy for all databases is included in 
Appendix A.  
  
Study Selection 
 
Literature search results identified by the search strategy were uploaded to Covidence and 
all titles and abstracts were reviewed by a single author (JZ). Inclusion and exclusion criteria 
were developed for the population, intervention, comparators, outcomes, timing, setting, and 
study designs (Table 1). The eligible intervention was defined as use of a LARC, which included 
progestin IUD, copper IUD, or subdermal contraceptive implants. The eligible comparison was 
use of hormonal SARCs, which include: oral contraceptive pills (OCPs), vaginal ring, patch, and 
depot medroxyprogesterone acetate (DMPA) injection. Dual method use was defined as use of a 
hormonal method or copper IUD with a concurrent barrier method. All STIs were considered 
including, but not limited to, chlamydia, gonorrhea, syphilis, HIV, HPV, HSV, and trichomonas.  
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Table 1. Inclusion and Exclusion Criteria 
  
Inclusion Exclusion 
Populations Sexually active, female adolescent and 
young adults aged 14-24 years old 
Studies comprise solely in specialized 
populations such as individuals with 
HIV/AIDS, sex workers, LGBTQ  
Intervention LARCs including Progestin IUDs 
Copper-IUD, and/or Implantable Rod 
Non-LARCs 
Comparisons Non-intervention hormonal SARCs: 
injection, patch, ring, and/or OCPs 
 
Outcomes Dual Method Use or STI incidence  
 
Timing Studies published since 1988, At least 
3 months duration of contraception use 
Studies published prior to 1988 
Setting United States Non-United States 
Study 
Designs 
RCT, Retrospective or Prospective 
Cohort, and Case-Control 
Cross-sectional studies, case series, 
and case reports 
 
Studies were excluded if they were conducted in a non-United States population or 
special populations such as individuals with HIV/AIDS or sex workers. These populations were 
excluded due to concerns that outcomes of studies conducted in these populations would be less 
applicable to the general population. Studies that included these special populations within a 
larger population were eligible.  Eligible studies included randomized controlled trials (RCTs), 
cohort studies, and case-control studies. Cross-sectional studies, case series, and case reports 
were excluded. 
 Full texts were obtained for all abstracts that potentially met inclusion criteria or if there 
was any uncertainty about their eligibility. References without abstracts that could have been 
relevant were also included for full text screening. Many references that underwent full-text 
screening were only abstracts or posters. Without full texts, inclusion criteria and risk of bias 
were unable to be adequately assessed; thus, they were excluded.  
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Data Extraction and Risk of Bias Assessment 
 
Data extraction was completed using a structured data abstraction form for each included 
article. Information about the methodology, population, intervention, comparators, outcomes, 
settings, and designs were extracted. Any uncertainties were attempted to be resolved by 
contacting study authors. The Cochrane Collaboration’s tool for determining risk of bias in RCTs 
(RoB 2.0) was used, which assessed whether bias occurred from the randomization process, 
deviations from intended interventions, missing outcome data, measurement of the outcome, and 
selection of the reported result.26 The Risk of Bias in Non-randomized Studies of Interventions 
(ROBINS-I) tool for cohort studies was used, which assessed whether bias occurred due to 
confounding, selection of participants, classification of interventions, deviations from intended 
interventions, missing data, measurement of outcomes, and selection of reported results.27 The 
studies were rated as low, moderate, serious, or critical risk of bias. 26,27 No methods were used 
to determine whether studies identified were biased due to non-study related processes.  
 
Data Synthesis and Analysis 
 
Findings were summarized in tabular and narrative form. The primary summary measure 
was risk ratio. To determine whether meta-analyses were appropriate, the clinical and 
methodological heterogeneity of the studies was assessed following established guidance.28 
Given the clinical and methodological heterogeneity of the studies, meta-analysis of the studies 
would not be appropriate. The strength of evidence was assessed and reported according to 
established guidance based on domains related to risk of bias, consistency, precision, and 
directness.29 The outcomes of dual method use and STI incidence were graded as high (high 
confidence that the evidence reflects the true effect), moderate (moderate confidence that the 
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evidence reflects the true effect), low (low confidence that the evidence reflects the true effect), 
or insufficient (no evidence). 
 
Results 
 
Study selection 
The search strategy identified 1313 citations, of which 225 were duplicates (Figure 1). 
Title and abstract screening of the 1088 unique citations resulted in 35 studies for full-text 
review. Of these, 5 articles met criteria for inclusion in the systematic review.30–34 The primary 
reasons for exclusion were unavailability of a full text article, wrong outcome, wrong patient 
population, or wrong intervention. No additional citations were identified by review of 
references. Of included studies, one was a cluster randomized trial and the remaining were 
prospective cohort studies.  
 
Figure 1. Summary of Literature Search and Selection  
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Study Characteristics  
Characteristics of included studies are presented in Table 2. Three of the studies 31–33 
were conducted within the adolescent population with implants as the only LARC contraceptive.  
One study 30 was conducted in both adolescents and young women and included both IUD and 
Implants contraceptive users. One study 34 was conducted in young women and included both 
IUD and Implant contraceptive users. Participants in all but one study initiated their 
contraceptive method at time of enrollment. Study sample sizes ranged from 210 to 1500. Follow 
up time ranged from 6 months to 24 months.  
 
Risk of Bias 
The overall risk of bias is presented in Table 3, and in further detail in Table 4 and 5. 
Overall, two studies were determined to have critical risk of bias 32,33, one to have serious risk of 
bias 31, one to have moderate risk of bias 30, and one to have low risk of bias 34. Almost all 
prospective cohort studies had serious risk of bias due to confounding as there were statistically 
significant differences in baseline demographics and risk factors between groups that were not 
accounted for in data analyses. Three studies 31–33 provided limited or no information on how 
participants were selected into the studies. Many of the studies were fraught with high attrition 
and low adherence (eg. > 50% loss to follow up and > 30% deviation from contraceptive method 
at enrollment) and thus high potential for attrition bias. SARC users were less adherent to their 
contraceptive method than LARC users and were much more likely to deviate from their 
contraceptive method (eg. switch to condoms only or another SARC method). Analyses for most 
studies only included participants that followed up and were adherent to their contraceptive. No 
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studies assessed characteristics of the participants that deviated from their contraceptive method 
or those that were lost to follow up. Classification of interventions was completed at time of 
enrollment and self-reported at follow up time frames. Dual method use and STI incidence were 
based on participant self-response, which are subject to both recall and reporting bias. However, 
it is unlikely that this bias would differ between users of different contraceptive methods and 
thus less likely to bias the comparative results.  
 
Dual Method Use Outcome 
 
Three prospective cohort studies 30,32,33 and one cluster randomized trial 34 compared dual 
method use among adolescents and young women who used LARCs and SARCs. Table 6 
summarizes the findings from these studies. Two studies 30,32 found decreased dual method use 
among LARC users and two studies 33,34 found no difference in dual method use between LARC 
and SARC users. However, approach to measurement of dual method use varied significantly 
between the studies and many analyses did not adjust for potential confounders or baseline 
differences between comparison groups.  
Bastow et al 30 reported a prospective cohort study of 1048 English speaking adolescents 
and young women recruited from a clinic in Aurora, Colorado who used IUDs, implants, OCPs, 
patches, vaginal ring, and DPMA as contraceptive methods. The authors measured dual method 
use by querying participants whether they used a condom even once since enrollment into the 
study. They reported that LARC users were less likely than SARC users to ever engage in dual 
method use at 6 months (RR 0.69 [95% CI 0.57 to 0.83]). The authors reported that odds of dual 
method use was still lower among individuals who used LARCs as compared to SARCs (aOR 
0.48 [95% CI 0.31-0.74]) after adjusting for age <20 and new sexual partner.  
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Bastow et al also assessed changes in dual method use by querying participants whether 
their condom use had increased, stayed the same, or decreased after initiating their contraceptive 
method, which was different between LARC and SARC users (χ2 = 8.97, 2 [n=508], p = 0.01). 
LARC users were 1.33 (95% CI 0.99 to 1.82) times as likely as SARC users to report decrease in 
condom use frequency than increasing or staying the same. The authors also found that among 
individual without new sexual partners, LARC users were less likely than SARC users to engage 
in dual method use (RR 0.66 [95% CI 0.53-0.88]). However, among individuals with new sexual 
partners, LARC users were still less likely than SARC users to engage in dual method use (RR 
0.72 [95% CI 0.57-0.91]). Overall, the authors found that individuals with a new sexual partner 
had higher odds of engaging in dual method use (aOR, 3.29 [95% CI 2.30-5.26]).  
Darney et al 32 reported a prospective cohort study of 399 English or Spanish speaking 
adolescent (13-19 years of age) recruited from 5 clinics throughout San Francisco, CA who used 
implants and OCPs. The study assessed dual method use by querying whether participants used a 
condom at last sexual intercourse and found that LARC users were less likely to engage in dual 
method use at 12 months (RR 0.51 [95% CI 0.29 to 0.91]) and 24 months (RR 0.48 [95% CI 0.28 
to 0.82]). The authors also assessed dual method use by querying frequency of condom use with 
participants selecting a predetermined response of every time, most of the time, about half the 
time, hardly ever, or never. A statistically significant difference between implant and OCP users 
on the frequency of condom use was reported at both 12 months (χ2 = 11.78, 2 [n=126], p = 
0.003) and 24 months (χ2 = 6.88, 2 [n=97], p = 0.03), but not at baseline (χ2 = 5.86, 2 [n=296], p 
= 0.053). 
Dinerman et al 33 reported a prospective cohort study of 210 adolescent females (12-18 
years old) recruited from a clinic in Baltimore, MD who used implants and OCPs. Authors 
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assessed dual method use by querying whether participants used a condom at last sexual 
intercourse and reported no statistically significant differences between the two groups at 6 
months (RR 0.99 [95% CI 0.78 to 1.26]). The authors also assessed dual method use by querying 
frequency of condom in a similar fashion as Darney et al and reported no difference in the 
frequency of condom use between implant and oral contraceptive choosers at 6 months (χ2 = 
6.88, 2 [n=97], p = 0.54). However, baseline frequency of condom use was not reported.  
El Ayadi et al 34 reported a secondary analysis of a cluster randomized controlled trial of 
an educational intervention targeting providers to increase access to LARC methods among 1500 
young women (18-25 years old). LARC use was 16.8% and 27.9% among the standard care 
group and educational intervention group, respectively. The authors measured dual method use 
by querying whether participants used a condom in conjunction with hormonal IUD, implant, 
Depo-Provera injection, pill, vaginal ring or transdermal patch, copper IUD, or sterilization at 
last sexual intercourse. The authors report that the educational intervention did not change dual 
method use (RR 0.98 [95% CI 0.75 to 1.29]) despite higher LARC uptake in the intervention 
group. After adjusting for age, race/ethnicity, insurance, primary partner, STI history, parity, and 
practice setting, the effect of educational intervention on dual method use was still not 
statistically significant (aOR 1.03, (95% CI 0.74-1.44). When stratified by contraceptive method, 
the study reported that SARC users had higher adjusted odds of engaging in dual method use 
than LARC users (aOR 2.60 [95% CI 1.56-4.32]). El Ayadi et al also reported that individuals 
with a primary partner had lower odds of dual method use (aOR, 0.48 [95% CI 0.30 - 0.76]).  
 
STI Incidence Outcome 
 
Three of the 4 studies contributing to evidence regarding dual method outcomes also 
reported on STI incidences. An additional study (that did not report on the dual method outcome) 
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for a total of three prospective cohort studies 31–33 and one cluster randomized trial 34 with 1500 
participants compared STI incidences between adolescents and young women who used LARCs 
and SARCs. Table 7 summarizes the findings from these studies. Overall, no study found a 
statistically significant difference in STI incidence between LARC and SARC users. The STIs 
measured varied by study, but all included chlamydia, gonorrhea, and trichomoniasis except for 
Darney et al which did not specify which STIs were measured. Dinerman et al explicitly 
excluded measurement of herpes, HPV, HIV as the authors did not believe they could determine 
whether subjects acquired the infection during or prior to the start of the study. 
Cromer et al was a prospective cohort study of 199 adolescent and young women (11-20 
years of age) recruited from a clinic in Columbus, OH who used Norplant, OCP, and DPMA as 
contraceptives. There was no difference in STI incidence between Norplant and OCP users (RR 
1.69 [95% CI 0.35 to 8.07]), Norplant and DMPA users (RR 1.19 [95% CI 0.34 to 4.09]), or 
Norplant and OCP/DMPA users (RR 1.35 [95% CI 0.44 to 4.15]). 
Similarly, there was no statistically significant difference in STI incidence between users 
of LARCs and SARCs reported in any of the following studies: Darney et al (RR 1.27 [95% CI 
0.31 to 5.20]), Dinerman et al (RR 1.05 [95% CI 0.60 to 1.86]), and El Ayadi et al (RR 1.12 
[95% CI 0.85 to 1.47]). El Ayadi et al 34 also estimated STI incidence with Kaplan-Meier 
survival estimates and reported 14.5 diagnosis per 100 person-years in the control group and 16.5 
diagnosis per 100 person-years in the intervention group. STI incidence did not differ 
significantly between the intervention and control groups in unadjusted (HR 1.14, (95% CI 0.84-
1.54) and adjusted models (aHR 1.20, (95% CI 0.88-1.64).  
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Strength of Evidence 
Overall, the strength of evidence on the effects of LARC uptake on dual method use is 
low given the study limitations, inconsistency of results, and indirectness of evidence for the 
high-quality study (Table 8). Of the prospective cohort studies that reported dual method use, 
two 32,33 were found to have critical risk of bias and one 30 to have moderate risk of bias. The two 
studies 30,34 at low  and moderate risk of bias and with the largest population reported 
contradictory results. In general, two studies found significant reduction in dual method use after 
LARC uptake, and two studies found no difference. While the cluster randomized control trial 34 
was at low risk for bias, the evidence for dual method use was indirect. The trial assessed 
whether an educational intervention to increase LARC uptake affects dual method use rather 
than directly assessing whether LARC uptake affects dual method use. The authors reported 
there was no significant intervention effect on provider discussion of condoms; however, the 
possibility of co-intervention bias still exists. The other good-quality study 30 assessed dual 
method use with a very permissive and less sensitive definition.   
Overall, the strength of evidence on LARC effects on STI incidence is low given the 
study limitations, imprecision, and indirectness of evidence for the singular good quality study. 
Of the prospective cohort studies that reported STI incidence, three were found to have serious to 
critical risk of bias.31–33 All studies were underpowered to assess STI acquisition. As previously 
described, the El Ayadi et al study provided indirect evidence as the trial assessed whether an 
educational intervention to increase LARC uptake affected STI acquisition, rather than if LARC 
uptake affected STI acquisition.  
 
 
 13 
Discussion 
While the review suggests that studies on adolescents and young women who use LARCs 
as compared to SARCs have shown both lower and comparable rates of dual method use, STI 
incidence was shown to be comparable between the two groups. However, there are several 
limitations that reduce the reliability and applicability of these findings. The strength of evidence 
was low for both outcomes.  
This study illustrates that LARC use does not necessarily change dual method use and 
changes in dual method use do not necessarily result in changes in STI acquisition. The factors 
involved in deciding which contraceptive method to use are potential confounders for rates of 
dual method use and STI incidence. For example, individuals with primary partners are at less 
risk for acquiring a STI and thus less likely to use a condom. However, they might be more 
likely to choose a LARC for these reasons and reduced condom use is not a result of LARC 
uptake. However, the Bastow et al study shows that even with a new sexual partner and higher 
risk of STI acquisition, LARC users are still less likely than SARC users to use a condom even 
once. It is difficult to tease apart the true relationship without a randomized controlled study, 
which would not be practical. Contraceptive counseling of adolescents and young women should 
attempt to help them understand the relationship between these factors and their personal risk of 
pregnancy and STI acquisition. However, providers should continue to emphasize the need for 
both pregnancy and STI prevention during contraceptive counseling as partners and 
contraceptive methods frequently change.  
Study populations varied greatly in terms of demographics from one another, which is 
unsurprising as all but one of the included studies enrolled participants limited to a clinic or 
clinics within a single city. Many studies enrolled participants from urban, high risk clinics and 
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the majority of participants were minorities in all but one study that may not be representative of 
a general population of female adolescent and young adult. Only one study enrolled a nationally 
geographically representative population, but from a specialized reproductive health clinic that 
serves predominately low-income individuals. Significant differences in sexual behaviors and 
risk factors existed between LARC and SARC users at baseline.  
One limitation common to most included studies was high attrition and/or low adherence 
that left studies underpowered and at high risk for confounding. This limited the studies’ ability 
to draw conclusions on dual method use and STI incidence, and possibility of a type II error 
cannot be excluded. The relative risk of acquiring a STI was consistently higher among LARC 
users, but the difference between groups was not statistically significant. However, as the studies 
lacked power and results were not precise, it is possible that there could be a difference in STI 
incidence. 
The higher quality studies provide less direct evidence. The El Ayadi et al. study was a 
secondary analysis of a randomized control trial of a provider targeted educational intervention 
to promote increased LARC uptake. While the percentage of LARC users was higher in the 
intervention arm, it is uncertain whether this difference provided the necessary statistical power 
to detect a difference or whether there truly was no difference in STI incidence. There is also 
concern that the education intervention could have caused a cointervention bias that could have 
increased rates of dual method use in the intervention group. The Bastow et al. study utilized a 
very permissive measurement of dual method use that assessed whether a condom was ever used 
even once. While there is no gold standard to measure either dual method or condom use, this 
definition is broad and not a sensitive measurement of dual method use.   
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The timeframe of the literature search was selected to include all currently FDA approved 
LARC methods. Three of the studies were conducted using Norplant, an implant device that have 
since been withdrawn from the market. However, it is unlikely that reasons Norplant was 
removed from the market would affect dual method use and STI acquisition. In addition, studies 
were conducted in the 1990s or 2010s. It is uncertain whether potential changes in sexual 
practices and behaviors in these two decades may affect the applicability of the results from 
older studies to current adolescents and young women.  
Another limitation of this review is that we did not attempt to determine whether there 
could be a detection bias confounding the results. In typical use, SARC users might have higher 
rates of follow up requirements to receive their contraceptive such as DPMA every 3 months as 
compared to a LARC which does not require specific follow up. Increased interaction with 
medical personal can lead to increased screening and or diagnosis opportunities, which would 
not be a true increase in STI incidence. This potential bias is important since a majority of 
studies rely on self-reported STI incidence.  
 
Conclusion 
There is a lack of high quality, recent data on LARC use among adolescents and young 
women. While there have been some recent good quality studies, more high-quality studies are 
needed to strengthen the body of literature on whether use of LARCs changes dual method use 
and STI acquisition. Providers should continue to emphasize the need for both protection against 
pregnancy and STIs in adolescent and young women seeking contraception.  
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Table 2. Study Characteristics of Included Studies 
 
Author (Year) 
Study Design 
Setting Dates of 
Study 
Length 
of 
Follow-
Up 
Total 
Participants 
 
% Non-White 
Age, mean 
(SD) unless 
otherwise 
indicated 
Intervention 
(participants analyzed 
/ participants enrolled 
per outcome) 
Control 
(participants 
analyzed / 
participants enrolled 
per outcome) 
Risk of 
Bias 
Bastow (2018) 
 
Prospective 
Cohort 
Aurora, CO 
 
Hospital-affiliated Title X 
adolescent clinic 
Aug 
2011 to 
Feb 2013 
6 months 1048 
 
41.9% 
G1: 46.9% 
G2: 40.3% 
Median (range) 
 
G1: 20 (14-24) 
G2: 21 (13-24) 
IUD and Implant  
 
380 / 771 for Dual 
Method outcome 
Pills, Patch, Vaginal 
Ring, DPMA  
 
128 / 277 for Dual 
Method outcome 
Moderate	
Cromer (1994) 
 
Prospective 
Cohort 
Columbus, OH 
 
Hospital-affiliated adolescent 
health clinic 
NR 6 months 199 
 
63% - 67% 
Mean: 15.2 - 
15.7 
Range: 11-20 
years 
Norplant 
 
38 / 66 for STI 
outcome 
OCP and DPMA 
 
27 / 75 for STI 
outcome 
Serious	
Darney (1999) 
 
Prospective 
Cohort 
San Francisco, CA 
 
2 university-affiliated urban 
hospital clinics, 1 urban high 
school-based clinic, and 2 
suburban Planned Parenthood 
clinics 
NR 24 
months 
399 
 
G1: 79% 
G2: 84% 
G1: 16.4 (1.6) 
G2: 16.8 (1.5) 
Implant 
 
78 / 200 for both STI 
and Dual Method 
outcomes 
OCP 
 
17 / 100 for both 
STI and Dual 
Method outcomes 
Critical	
Dinerman 
(1995) 
 
Prospective 
Cohort 
Baltimore, MD 
 
Urban, university-affiliated, 
hospital adolescent clinic 
April 
1992 to 
May 
1993 
6 months 210 
 
 
G1: 94% 
G2: 87% 
 
G1: 16.3 (1.3) 
G2: 16.1 (1.6) 
Implant 
 
54 / 61 for STI 
outcome 
 
49 / 61 for Dual 
method outcome 
OCP 
 
64 / 80 for STI 
outcome 
 
57 / 80 for Dual 
method outcome 
Critical	
El Ayadi (2017) 
 
Cluster 
Randomized 
Control 
Planned Parenthood clinics 
throughout the US 
May 
2011 to 
May 
2013 
24 
months 
1500 
 
50.7% 
G1: 51% 
G2: 50.4% 
G1: 21.5 (2.1) 
G2: 21.5 (2.3) 
Provider education to 
increase LARC 
uptake 
 
736 / 802 for STI 
outcome 
 
672 /802 for Dual 
method outcome 
Standard practice of 
care 
 
 
620 / 698 for STI 
outcome 
 
575 / 698 for Dual 
Method outcome 
Low	
 
NR: Not Reported, STIs: Sexually Transmitted Infections, IUD: Intrauterine Device, LARC: Long Acting Reversible Contraceptives, OCP: Oral 
Contraceptive Pills, DPMA: Depot medroxyprogesterone acetate 
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Table 3. Risk of Bias for Included Studies  
 
Author (Year) Overall Bias Overall Rationale for Bias Rating 
Bartow (2018) Moderate Moderate risk of bias across most domains. Overall attrition was > 50%, but percent attrition rates was comparable between the two 
groups. Participants who were nonadherent still followed up. It’s likely that the reason for missing data are similar. There were statically 
significant differences in baseline characteristics between the SARC and LARC group, and no data was collected on history of STIs or 
education. However, variables that evaluated demographic and sexual risk confounding domains were adjusted for in multivariable logistic 
regression model.  
Cromer (1994) Serious Serious risk of bias across multiple domains including: confounding, selection of participants into study, missing data. No information on 
deviations from intended intervention. Participants in the Implant and DPMA groups were provided extra education on condom use. 
Multiple demographic and sexual risk characteristics differed between contraceptive groups such as history of prior sexually transmitted 
infections, prior pregnancies, prior use of contraception, and prior delivery.  Primary analysis did not adjust for these potential 
confounders. Limited information on which participants were approached for inclusion into the study. Overall attrition was approximately 
50%. However, attrition rates were vastly different between groups (36-69%) and analysis was restricted to participants that followed up. 
Authors failed to present STI incidence at 6 mos.  
Darney (1999) Critical Critical bias due to deviations from intended interventions. Serious risk of bias due to confound and missing data. Implant continuation was 
82% and 64% at 1 and 2 years, respectively, whereas OCP continuation was 40% and 34% at 1 and 2 years, respectively. Condom use 
analysis was only conducted among participants with data at each time point, which was less than 40% and 17% of enrolled implant and 
OC users, respectively. There were not enough participants to power any differences. Analysis is unable to address potential risk of bias 
from this missing data. In addition, there were significant baseline differences between the OC and Implant group in terms of risk and 
sexual behavioral such as history of prior STI, prior pregnancy, prior birth, prior elective abortion, and substance use. During the study 
they were more likely to have more than one new partner during the first year. However, analysis did not adjust for these potential 
confounders. 
Dinerman (1995) Critical Critical bias due to deviations from intended interventions. Serious risk of bias across confounding, selection of participants into study, and 
measurement of outcome domains. No information was given on how the self-report and review of medical records were compared and 
percentage with STI was determined. Condom and STI incidence was analyzed by ITT, however, there was significant difference in 
contraceptive method adherence between the two groups with 87% continuation among Implant users and 42% of OCP users. Baseline 
characteristics was only provided for participants included in analysis and not for all participants enrolled. No information on participants 
who did not follow up and whether that population differed from analyzed population.  Implant users who already had the implant prior to 
or had insertion within 4 weeks of the initial interview were eligible. OCP users were those who were already taking or used OCPs after 
initial interview. No information provided on duration of prior use. There were differences in prior pregnancy, use of OCPs, and mother 
acting as head of the house between the analyzed groups. No information about baseline condom use. Primary analysis did not adjust for 
these confounders. Some differences between intervention follow up time from intervention up to double the intended time frame.  
El Ayadi (2017) Low Low risk of bias across all domains. Though randomization was stratified by clinic size, it was a presumed random allocation by an 
independent statistician. While participant selection occurred after the clinics were randomized, there is no evidence to suggest that 
selection of individuals would be affected by knowledge of the intervention. It is uncertain whether participants were aware whether their 
clinic received the educational intervention. Although dual method use and STI outcomes were dependent on self-reported data, it is 
unlikely that participants awareness they were in a trial would results in different responses by intervention. Outcome data was available 
for over 80% of participants and analysis was ITT.  There were some concerns on how STI incidence from self-report and medical record 
data was combined and determined. 
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Table 4. Risk of Bias by Domains for Cohort Studies  
 
Author 
(Year) 
Bias due to 
confounding 
Bias in selection of 
participants into 
the study 
Bias in 
classification of 
interventions 
Bias due to 
deviations from 
intended 
interventions 
Bias due to 
missing 
data 
Bias in 
measurement of 
outcome 
Bias in selection of 
the reported result Overall Bias 
Bastow 
(2018) Moderate Moderate Low Moderate Moderate Moderate Moderate Moderate 
Cromer 
(1994) Serious Serious Low No Information Serious Moderate Moderate Serious 
Darney 
(1999) Serious No Information Low Critical Serious Moderate Moderate Critical 
Dinerman 
(1995) Serious Serious Low Critical Moderate Serious Moderate Critical 
 
 
 
 
Table 5. Risk of Bias by Domains for Cluster Randomized Parallel Group Trial 
 
Author 
(Year) 
Bias arising from 
the 
randomization 
process 
Bias arising from the timing of 
identification and recruitment 
of individual participants in 
relation to timing of 
randomization 
Bias due to 
deviations from 
intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement of 
outcome 
Bias in selection of 
the reported result Overall Bias 
El Ayadi 
(2017) Low Low Low Low 
Dual Method Use - 
Low 
 
STI Incidence- 
Some Concerns 
Low Low 
STI: Sexually Transmitted Infections 
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Table 6. Dual Method Use by Study 
 
Author (Year) Control Intervention Measurement Follow Up Duration Measure of Association Risk of Bias 
Bastow (2018) Pills, Patch, 
Vaginal Ring 
(75.8%) 
 
DPMA (24.2%) 
IUD (49.8%)  
 
Implant 
(50.2%) 
Condom use, even once since last 
surveyed 
6 months RR 0.687 (95% CI 0.57 to 0.83) Moderate 
Change in condom use 
(“Increased”, “Stayed the same”, or 
“Decreased”) 
χ2 = 8.97, 2 [n=508], p = 0.01 
Darney (1999) OCP Norplant Condom use at last sexual intercourse 12 months RR 0.51 (95% CI 0.29 to 0.91) Critical 
24 months RR 0.48 (95% CI 0.28 to 0.82) 
Frequency of condom use  
(“Every time”, “Half” to “Most of the 
time”, or “Hardly ever” or “Never”) 
12 months χ2 = 11.78, 2 [n=126], p = 0.003 
24 months χ2 = 6.88, 2 [n=97], p = 0.03 
Dinerman 
(1995) 
OCP Implant Condom use at last sexual intercourse 6 months RR 0.99 (95% CI 0.78 to 1.26) Critical 
Frequency of condom use  
(“Every time”, “Most times”, “Half the 
time”, “Sometimes” or “Never”) 
χ2 = 6.88, 2 [n=97], p = 0.54 
El Ayadi (2017) Standard Care 
 
LARC (16.8%) 
IUD (13.5%) 
Implant (3.6%) 
Provider 
Education 
 
LARC 
(27.9%) 
IUD (19%) 
Implant 
(9.9%) 
Condom use in conjunction with 
hormonal IUD, implant, Depo-Provera 
injection, pill, vaginal ring or 
transdermal patch, copper IUD, or 
sterilization at last sexual intercourse 
12 months RR 0.98 (95% CI 0.75 to 1.29) Low 
 
OCP: Oral Contraceptive Pills, DPMA: Depot medroxyprogesterone acetate, IUD: Intrauterine Device, LARC: Long acting reversible 
contraceptives 
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Table 7. STI Incidence by Study 
 
Reference Intervention Control Follow Up Duration Measured STIs 
Relative Risk 
for LARCs vs 
SARCs 
95% Confidence 
Interval Risk of Bias 
Cromer (1994) Norplant 
OCP 
3 months Gonorrhea, Chlamydia, Trichomoniasis, and Herpes 
1.69 0.35 to 8.07 
Serious DPMA 1.19 0.34 to 4.09 
OCP and DPMA 1.35 0.44 to 4.15 
Darney (1999) Norplant OCP 24 months Not Reported 1.27 0.31 to 5.20 Critical 
Dinerman (1995) Norplant OCP 6 months Cervicitis, Gonorrhea, Chlamydial, Trichomoniasis 1.05 0.60 to 1.86 Critical 
El Ayadi (2017) Provider Education Standard Care 12 months 
Gonorrhea, Chlamydia, 
Trichomoniasis, Herpes, 
HPV, Syphilis, Hepatitis B, 
HIV/AIDS 
1.12 0.85 to 1.47 Low 
 
STIs: Sexually Transmitted Infections; OCP: Oral Contraceptive Pills, DPMA: Depot medroxyprogesterone acetate, HPV: Human Papillomavirus 
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Table 8. Strength of Evidence  
 
Outcome Certainty Assessment Magnitude of Effect Strength of 
Evidence # of Studies / 
# of Subjects 
Risk of Bias; Design / 
Quality (#) 
Consistency Directness Precision 
Dual 
Method 
Use 
4 / 3157 High ; 
 
 Prospective Cohort (4) 
and Cluster RCT (1) /  
 
Low (1), Moderate (1), 
and Critical (2) 
Inconsistent Direct Imprecise Two studies found 
significant reduction 
and two studies found 
no difference.  
Low 
STI 
Incidence 
4 / 2308 High ; 
 
Prospective Cohort (3) 
and Cluster RCT (1) /  
 
Low (1), Serious (1), 
Critical (2) 
Consistent Direct Imprecise No studies found a 
statistically significant 
difference in STI 
incidence.   
Low 
 
STI – Sexually Transmitted Infection 
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Appendix A. Search strategy by Database for PubMed, CINAHL, Cochrane, Embase, and ClinicalTrials.gov 
 
PubMed (MEDLINE) 
Set 
# 
 Results 
1 "Long-Acting Reversible Contraception"[Mesh] OR (long-acting reversible[tiab] AND (contraception[mesh] OR contraceptive[tiab] OR contraceptives[tiab] 
OR contraception[tiab] OR contraceptions[tiab])) OR LARC[tiab] OR LARCs[tiab] OR "Intrauterine Devices"[Mesh] OR “intrauterine Device”[tiab] OR 
“intrauterine Devices”[tiab] OR IUD[tiab] OR IUDs[tiab] OR “Intrauterine Contraceptive Device”[tiab] OR “Intrauterine Contraceptive Devices”[tiab] OR 
"etonogestrel"[Supplementary Concept] OR nexplanon[tiab] OR implanon[tiab] OR Implant[tiab] OR implantable[tiab] 
143314 
2 "Young Adult"[Mesh] OR "Adolescent"[Mesh] OR “young adult”[tiab] OR “young adults”[tiab] OR “young women”[tiab] OR “young woman”[tiab] OR 
adolescent[tiab] OR adolescents[tiab] OR adolescence[tiab] OR teenager[tiab] OR teenaged[tiab] OR teenagers[tiab] OR teen[tiab] OR teens[tiab] OR 
youth[tiab] 
2275040 
3 “Sexually Transmitted Diseases"[Mesh] OR "Sexually Transmitted Diseases"[tiab] OR “sexually transmitted disease”[tiab] OR STD[tiab] OR STDs[tiab] 
OR "Sexually Transmitted Infections"[tiab] OR “sexually transmitted infection”[tiab] OR STI[tiab] OR STIs[tiab] OR “venereal diseases”[tiab] OR 
“venereal disease”[tiab] OR "Condoms, Female"[Mesh] OR "Condoms"[Mesh] OR condom[tiab] OR condoms[tiab] OR “barrier method”[tiab] OR “barrier 
methods”[tiab] OR “barrier contraceptive”[tiab] OR “barrier contraceptives”[tiab] OR “barrier contraception”[tiab] OR “barrier contraceptions”[tiab] OR 
“dual method”[tiab] OR “dual methods”[tiab] OR “dual contraceptive”[tiab] OR “dual contraceptives”[tiab] OR “dual contraception”[tiab] OR “dual 
contraceptions”[tiab] 
338469 
4 #1 AND #2 AND #3 994 
5 #4 AND English[lang] AND "1988"[Date - Publication] : "3000"[Date - Publication] 661 
 
CINAHL 
Set 
# 
 Results 
1 ((TI (long-acting reversible) OR AB (long-acting reversible)) AND (MH "Contraception" OR TI (contraceptive OR contraceptives OR contraception OR 
contraceptions) OR AB (contraceptive OR contraceptives OR contraception OR contraceptions))) OR MH "Intrauterine Devices" OR TI (LARC OR LARCs 
OR “intrauterine Device” OR “intrauterine Devices” OR IUD OR IUDs OR “Intrauterine Contraceptive Device” OR “Intrauterine Contraceptive Devices” 
OR nexplanon OR implanon OR Implant OR implantable) OR AB (LARC OR LARCs OR “intrauterine Device” OR “intrauterine Devices” OR IUD OR 
IUDs OR “Intrauterine Contraceptive Device” OR “Intrauterine Contraceptive Devices” OR nexplanon OR implanon OR Implant OR implantable) 
37846 
2 MH "Young Adult" OR MH "Adolescence+" OR TI (“young adult” OR “young adults” OR “young women” OR “young woman” OR adolescent OR 
adolescents OR adolescence OR teenager OR teenaged OR teenagers OR teen OR teens OR youth) OR AB (“young adult” OR “young adults” OR “young 
women” OR “young woman” OR adolescent OR adolescents OR adolescence OR teenager OR teenaged OR teenagers OR teen OR teens OR youth) 
529761 
3 MH "Sexually Transmitted Diseases+" OR TI ("Sexually Transmitted Diseases" OR “sexually transmitted disease” OR STD OR STDs OR "Sexually 
Transmitted Infections" OR “sexually transmitted infection” OR STI OR STIs OR “venereal diseases” OR “venereal disease” OR MH "Condoms+" OR 
condom OR condoms OR “barrier method” OR “barrier methods” OR “barrier contraceptive” OR “barrier contraceptives” OR “barrier contraception” OR 
“barrier contraceptions” OR “dual method” OR “dual methods” OR “dual contraceptive” OR “dual contraceptives” OR “dual contraception” OR “dual 
contraceptions”) OR AB ("Sexually Transmitted Diseases" OR “sexually transmitted disease” OR STD OR STDs OR "Sexually Transmitted Infections" OR 
“sexually transmitted infection” OR STI OR STIs OR “venereal diseases” OR “venereal disease” OR MH "Condoms+" OR condom OR condoms OR 
“barrier method” OR “barrier methods” OR “barrier contraceptive” OR “barrier contraceptives” OR “barrier contraception” OR “barrier contraceptions” OR 
“dual method” OR “dual methods” OR “dual contraceptive” OR “dual contraceptives” OR “dual contraception” OR “dual contraceptions”) 
89920 
4 #1 AND #2 AND #3 248 
5 #4 AND English AND 1988- 244 
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Cochrane 
Set 
# 
 Results 
1 [mh "Long-Acting Reversible Contraception"] OR (long-acting reversible:ti,ab AND ([mh “contraception”] OR contraceptive:ti,ab OR contraceptives:ti,ab 
OR contraception:ti,ab OR contraceptions:ti,ab)) OR LARC:ti,ab OR LARCs:ti,ab OR [mh “Intrauterine Devices”] OR ‘intrauterine Device’:ti,ab OR 
‘intrauterine Devices’:ti,ab OR IUD:ti,ab OR IUDs:ti,ab OR ‘Intrauterine Contraceptive Device’:ti,ab OR ‘Intrauterine Contraceptive Devices’:ti,ab OR 
nexplanon:ti,ab OR implanon:ti,ab OR Implant:ti,ab OR implantable:ti,ab 
9037 
2 [mh “young adult”] OR [mh “Adolescent”] OR ‘young adult’:ti,ab OR ‘young adults’:ti,ab OR ‘young women’:ti,ab OR ‘young woman’:ti,ab OR 
adolescent:ti,ab OR adolescents:ti,ab OR adolescence:ti,ab OR teenager:ti,ab OR teenaged:ti,ab OR teenagers:ti,ab OR teen:ti,ab OR teens:ti,ab OR 
youth:ti,ab 
121713 
3 [mh “Sexually Transmitted Diseases”] OR ‘Sexually Transmitted Diseases’:ti,ab OR ‘sexually transmitted disease’:ti,ab OR STD:ti,ab OR STDs:ti,ab OR 
‘Sexually Transmitted Infections’:ti,ab OR ‘sexually transmitted infection’:ti,ab OR STI:ti,ab OR STIs:ti,ab OR ‘venereal diseases’:ti,ab OR ‘venereal 
disease’:ti,ab OR [mh “Condoms, Female"] OR [mh "Condoms"] OR condom:ti,ab OR condoms:ti,ab OR ‘barrier method’:ti,ab OR ‘barrier methods’:ti,ab 
OR ‘barrier contraceptive’:ti,ab OR ‘barrier contraceptives’:ti,ab OR ‘barrier contraception’:ti,ab OR ‘barrier contraceptions’:ti,ab OR ‘dual method’:ti,ab OR 
‘dual methods’:ti,ab OR ‘dual contraceptive’:ti,ab OR ‘dual contraceptives’:ti,ab OR ‘dual contraception’:ti,ab OR ‘dual contraceptions’:ti,ab 
23892 
4 #1 AND #2 AND #3 71 
5 #4 AND 1988- 57 
 
Embase 
Set 
# 
 Results 
1 'long-acting reversible contraception'/exp OR (long-acting reversible:ti,ab AND ('contraception'/exp OR contraceptive:ti,ab OR contraceptives:ti,ab OR 
contraception:ti,ab OR contraceptions:ti,ab)) OR LARC:ti,ab OR LARCs:ti,ab OR 'intrauterine contraceptive device'/exp OR ‘intrauterine Device’:ti,ab OR 
‘intrauterine Devices’:ti,ab OR IUD:ti,ab OR IUDs:ti,ab OR ‘Intrauterine Contraceptive Device’:ti,ab OR ‘Intrauterine Contraceptive Devices’:ti,ab OR 
'etonogestrel'/exp OR nexplanon:ti,ab OR implanon:ti,ab OR Implant:ti,ab OR implantable:ti,ab 
178017 
2 'young adult'/exp OR 'adolescent'/exp OR ‘young adult’:ti,ab OR ‘young adults’:ti,ab OR ‘young women’:ti,ab OR ‘young woman’:ti,ab OR adolescent:ti,ab 
OR adolescents:ti,ab OR adolescence:ti,ab OR teenager:ti,ab OR teenaged:ti,ab OR teenagers:ti,ab OR teen:ti,ab OR teens:ti,ab OR youth:ti,ab 
1803240 
3 'sexually transmitted disease'/exp OR ‘Sexually Transmitted Diseases’:ti,ab OR ‘sexually transmitted disease’:ti,ab OR STD:ti,ab OR STDs:ti,ab OR 
‘Sexually Transmitted Infections’:ti,ab OR ‘sexually transmitted infection’:ti,ab OR STI:ti,ab OR STIs:ti,ab OR ‘venereal diseases’:ti,ab OR ‘venereal 
disease’:ti,ab OR 'condom'/exp OR 'female condom'/exp OR condom:ti,ab OR condoms:ti,ab OR 'barrier contraception'/exp OR ‘barrier method’:ti,ab OR 
‘barrier methods’:ti,ab OR ‘barrier contraceptive’:ti,ab OR ‘barrier contraceptives’:ti,ab OR ‘barrier contraception’:ti,ab OR ‘barrier contraceptions’:ti,ab OR 
‘dual method’:ti,ab OR ‘dual methods’:ti,ab OR ‘dual contraceptive’:ti,ab OR ‘dual contraceptives’:ti,ab OR ‘dual contraception’:ti,ab OR ‘dual 
contraceptions’:ti,ab 
133103 
4 #1 AND #2 AND #3 1062 
5 #4 AND [embase]/lim NOT ([embase]/lim AND [medline]/lim) AND [english]/lim AND [1988-2018]/py 344 
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CT.gov 
Set 
# 
 Results 
1 (long-acting reversible AND (contraceptive OR contraceptives OR contraception OR contraceptions)) OR LARC OR LARCs OR “intrauterine 
Device” OR “intrauterine Devices” OR IUD OR IUDs OR “Intrauterine Contraceptive Device” OR “Intrauterine Contraceptive Devices” OR 
etonogestrel OR nexplanon OR implanon OR Implant OR implantable 
143314 
2 “young adult” OR “young adults” OR “young women” OR “young woman” OR adolescent OR adolescents OR adolescence OR teenager OR 
teenaged OR teenagers OR teen OR teens OR youth 
2275040 
3 "Sexually Transmitted Diseases" OR “sexually transmitted disease” OR STD OR STDs OR "Sexually Transmitted Infections" OR “sexually 
transmitted infection” OR STI OR STIs OR “venereal diseases” OR “venereal disease” OR condom OR condoms OR “barrier method” OR 
“barrier methods” OR “barrier contraceptive” OR “barrier contraceptives” OR “barrier contraception” OR “barrier contraceptions” OR “dual 
method” OR “dual methods” OR “dual contraceptive” OR “dual contraceptives” OR “dual contraception” OR “dual contraceptions” 
338469 
4 #1 AND #2 AND #3 7 
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Appendix B. Quality Ratings for Cohort Studies - Bias due to confounding 
 
Author 
(Year) 
Bias due to 
confounding 
Potential 
for 
confounding 
of the effect 
of 
intervention 
in this 
study? 
Was the 
analysis 
based on 
splitting 
participants' 
follow up 
time 
according to 
intervention 
received? 
Were 
intervention 
discontinuations 
or switches 
likely to be 
related to 
factors that are 
prognostic for 
the outcome? 
Did the 
authors use 
an 
appropriate 
analysis 
method that 
controlled for 
all the 
important 
confounding 
domains? 
Were 
confounding 
domains that 
were 
controlled for 
measured 
validly and 
reliably by 
the variables 
available in 
this study? 
Did the 
authors 
control for 
any post-
intervention 
variables that 
could have 
been affected 
by the 
intervention? 
Comments 
Bartow 
(2018) 
Serious Yes No NA No NA No There were statically significant 
differences in baseline characteristics 
between the SARC and LARC 
groups. No data on incidence of STIs 
or education. However, variables 
that evaluated demographic and 
sexual risk confounding domains 
were adjusted for in multivariable 
logistic regression model.  
Cromer 
(1994) 
Serious Yes No NA No NA No Multiple demographic and sexual 
risk characteristics differed between 
contraceptive groups such as history 
of prior sexually transmitted 
infections, prior pregnancies, prior 
use of contraception, and prior 
delivery. However, primary analysis 
did not adjust for these potential 
confounders.  
Darney 
(1999) 
Serious Yes No NA No NA No Authors collected variables that 
address demographic and sexual risk 
confounding domains. OC group at 
baseline were less likely to have 
history of prior STI, prior pregnancy, 
given birth, or had an elective 
abortion. During the study they were 
more likely to have more than one 
new partner during the first year. 
However, analysis did not adjust for 
these potential confounders.  
Dinerman 
(1995) 
Serious Yes No NA No NA No Baseline characteristics was only 
provided for participants included in 
analysis (not lost to follow up). No 
 26 
information provided on participants 
who did not enroll and whether that 
population differed from analyzed 
population. No information about 
baseline condom use. Collected 
variables measuring demographic 
and sexual risk confounding domains 
and found differences in prior 
pregnancy, use of OCPs, and mother 
acting as head of the house among 
population among participants that 
followed up. Uncertain what 
implications having a mother who is 
head of the house would have. 
Nevertheless, primary analysis did 
not adjust for these confounders. 
However, stronger indicators such as 
history of STI, sexual activity, 
number of partners were similar. 
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Appendix C. Quality Ratings for Cohort Studies - Bias in selection of participants into the study 
 
Author 
(Year) 
Bias in 
selection of 
participants 
into the 
study 
Was selection of 
participants into the 
study (or into the 
analysis) based on 
participant 
characteristics 
observed after the 
start of 
intervention? 
Were the post-
intervention 
variables that 
influenced 
selection likely 
to be associated 
with 
intervention? 
Were the post-
intervention 
variables that 
influenced 
selection likely to 
be influenced by 
the outcome or a 
cause of the 
outcome? 
Do start of 
follow-up and 
start of 
intervention 
coincide for 
most 
participants? 
Were 
adjustment 
techniques used 
that are likely 
to correct for 
the presence of 
selection 
biases? 
Comments 
Bartow 
(2018) 
Moderate Yes No Yes Yes No Of 1964 eligible initiation visits, 766 were 
not approached and 438 were missed. No 
explanation provided, but unlikely to affect 
balance between groups. However, 258 
visits were excluded due to lateness to 
appointment, which may have a weak 
influence on outcome.  
Cromer 
(1994) 
Serious Yes Yes No Yes NA Limited information on which participants 
were approached for inclusion into the 
study. Analysis was limited to participants 
that followed up, which could be associated 
with contraceptive disuse. However, this 
would be unlikely to influenced by STI 
contraction.  
Darney 
(1999) 
No 
Information 
Not Indicated / Yes Not Indicated Not Indicated Yes NA Authors do not provide any information on 
participant enrollment process other than 
inclusion and exclusion criteria.  
Dinerman 
(1995) 
Serious Yes NA NA No No Implant users who already had the implant 
prior to or had insertion within 4 weeks of 
the initial interview were eligible. OCP 
users were those who were already taking or 
used OCPs after initial interview. No 
information provided number of or duration 
for use these users. Some differences 
between intervention follow up time from 
intervention up to double the intended time 
frame. However, appears minimal and time 
difference not statistically significant per 
authors. Only participants that followed up 
were included in the analysis. 
 
 28 
Appendix D. Quality Ratings for Cohort Studies - Bias in classification of interventions 
 
Author 
(Year) 
Bias in 
classification 
of 
interventions 
Were 
intervention 
groups clearly 
defined? 
Was the information 
used to define 
intervention groups 
recorded at the start of 
the intervention? 
Could classification of 
intervention status have been 
affected by knowledge of the 
outcome or risk of the 
outcome? 
Comments 
Bartow 
(2018) 
Moderate Yes Yes No Contraceptives were defined and assessed at initial 
interview and at subsequent follow up times. No 
assessment of duration of use in between follow up time. 
However, intervention classification was unable to be 
affected by knowledge of the outcome. 
Cromer 
(1994) 
Moderate Yes Yes No Contraceptives were defined and assessed at initial 
interview and at subsequent follow up times. No 
assessment of duration of use in between follow up time. 
However, intervention classification was unable to be 
affected by knowledge of the outcome. 
Darney 
(1999) 
Moderate Yes Yes No Contraceptives were defined and assessed at initial 
interview and at subsequent follow up times. No 
assessment of duration of use in between follow up time. 
However, intervention classification was unable to be 
affected by knowledge of the outcome. 
Dinerman 
(1995) 
Moderate Yes Yes No Contraceptives were defined and assessed at initial 
interview and at subsequent follow up times. No 
assessment of duration of use in between follow up time. 
However, intervention classification was unable to be 
affected by knowledge of the outcome. 
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Appendix E.  Quality Ratings for Cohort Studies - Bias due to deviations from intended interventions 
 
 
Author 
(Year) 
Bias due to 
deviations 
from intended 
interventions 
Were important 
co-interventions 
balanced across 
intervention 
groups? 
Was the 
intervention 
implemented 
successfully for 
most 
participants? 
Did study 
participants 
adhere to the 
assigned 
intervention 
regimen? 
Was an 
appropriate 
analysis used to 
estimate the effect 
of starting and 
adhering to the 
intervention? 
Comments 
Bartow 
(2018) 
Serious Yes Yes No No Deviation difference between the two groups is less 
than 30%. There was ~25% deviations in adherence 
within the SARC group, mostly to no method, as 
compared to ~6% deviation within the LARC group, 
which could all affect dual method use and STI 
incidence. Analysis based on ITT does not address 
this potential bias.  
Cromer 
(1994) 
No Information No Yes No Information No Participants in the Implant and DPMA groups were 
provided extra education on condom use, which could 
have affected STI incidence. Authors did not discuss 
adherence percentages of participants at 3 mos or 6 
mos follow up.  
Darney 
(1999) 
Critical Yes Yes No No Deviation difference between the two groups was > 
30%. Implant continuation was 82% and 64% at 1 
and 2 years respectively. OCP continuation was 40% 
and 34% at 1 and 2 years respectively. Such 
unbalanced deviations between groups are likely to 
affect the outcomes.   
Dinerman 
(1995) 
Critical Yes Yes No No Adherence difference between the two groups was 
>30%. Implant continuation was 87% compared to 
OCP of 42%.  
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Appendix F. Quality Ratings for Cohort Studies - Bias due to missing data 
 
Author 
(Year) 
Bias due 
to missing 
data 
Were 
outcome 
data 
available for 
all, or nearly 
all, 
participants? 
Were 
participants 
excluded due 
to missing 
data on 
intervention 
status? 
Were 
participants 
excluded due to 
missing data on 
other variables 
needed for the 
analysis? 
Are the 
proportion of 
participants 
and reasons for 
missing data 
similar across 
interventions? 
Is there 
evidence 
that results 
were robust 
to the 
presence of 
missing 
data? 
Comments 
Bartow 
(2018) 
Moderate No No No Yes No Overall attrition is > 50%, however attrition rates is 
comparable between both groups. Most likely the 
reasons for missing data are similar. Participants who 
were nonadherent (non-method) still followed up.  
However, analysis unlikely to remove risk of bias 
from missing data despite using ITT. 
Cromer 
(1994) 
Serious No No No No No Population size for the same group at the same 
timeframe vary as a result of missing data that is 
excluded. (Eg. Symptoms at 6 months for DPMA 
dysuria n=16, vaginal discharge n=14, vaginal itch 
n=15 etc) Overall attrition is approximately 50%, 
however attrition rates is vastly different between 
groups (36-69%). Uncertain why follow up is 
different as both DPMA and OCPs were refilled in 3 
mos increments. Analysis does not address risk of 
bias from missing data.  
Darney 
(1999) 
Serious No Yes Yes No No While participants lost to follow up is low (<15%). 
The authors do not present data for participants who 
did not continue either contraception at admission. 
Missing data differs between groups and is much 
higher (>60%) in control group. Analysis is unable to 
address potential risk of bias from this missing data. 
Condom use analysis was only conducted among 
participants with data at each time point, which was 
less than 40% and 17% of enrolled implant and OC 
users, respectively.  
Dinerman 
(1995) 
Moderate Yes No Yes Yes No Missing data less than 20% on average.  
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Appendix G. Quality Ratings for Cohort Studies - Bias in measurement of outcome 
 
Author 
(Year) 
Bias in 
measurement 
of outcome 
Could the 
outcome measure 
have been 
influenced by 
knowledge of the 
intervention 
received? 
Were outcome 
assessors aware 
of the 
intervention 
received by 
study 
participants? 
Were the 
methods of 
outcome 
assessment 
comparable 
across 
intervention 
groups? 
Were any 
systematic errors 
in measurement of 
the outcome 
related to 
intervention 
received? 
Comments 
Bartow 
(2018) 
Moderate Yes Yes Yes Yes While participant knowledge of her intervention 
could influence her response to question regarding 
condom use and STI incidence, it’s unlikely that this 
would differ based on intervention. Any errors in 
responses are also unlikely to be related to 
intervention status.   
Cromer 
(1994) 
Moderate Yes Yes Yes Yes While participant knowledge of her intervention 
could influence her response to question regarding 
condom use and STI incidence, it’s unlikely that this 
would differ based on intervention. Any errors in 
responses are also unlikely to be related to 
intervention status.   
Darney 
(1999) 
Moderate Yes Yes Yes No While participant knowledge of her intervention 
could influence her response to question regarding 
condom use and STI incidence, it’s unlikely that this 
would differ based on intervention. Any errors in 
responses are also unlikely to be related to 
intervention status.   
Dinerman 
(1995) 
Serious Yes Yes Yes Yes It is not clear whether STD measurement was by 
number of STDs of percentage of participants who 
had at least one STD. No information was given on 
how the self-report and review of medical records 
were compared and compiled.  
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Appendix H. Quality Ratings for Cohort Studies - Bias in selection of the reported result 
 
Author 
(Year) 
Bias in 
selection of 
the reported 
result 
Is the reported effect 
estimate likely to be selected, 
on the basis of the results, 
from multiple outcome 
measurements within the 
outcome domain? 
Is the reported effect 
estimate likely to be 
selected, on the basis of the 
results, from multiple 
analyses of the intervention-
outcome relationship? 
Is the reported effect 
estimate likely to be 
selected, on the basis of 
the results, from 
different subgroups? 
Comments 
Bartow 
(2018) 
Moderate No No No Results are reported by group and by new 
sexual partner, which was defined a priori. 
There is no indication of selection of reported 
analysis. 
Cromer 
(1994) 
Moderate Yes No No Authors failed to present STI incidence at 6 
mos.  
Darney 
(1999) 
Moderate No No No While most results are reported for participants 
who continued their admission contraception, 
this was defined a priori to initiation of the 
study. Admission, 1 year, and 2-year data are 
presented for all variables. There is no 
indication of selection of reported analysis.  
Dinerman 
(1995) 
Moderate No No No Authors presented data for all intended 
outcomes at all intended timeframes. No 
indication of selected of reported analyses.  
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Appendix I. Quality Rating for Cluster Randomized Trial  
 
Bias domain Signaling questions Response  Description/Support for judgement 
Bias arising 
from the 
randomization 
process 
1a.1 Was the allocation sequence random?  Probably Yes  Randomization was stratified by clinic size by a 
computer-generated schedule by an independent 
statistician.  
1a.2 Is it likely that the allocation sequence was subverted? No 
1a.3 Were there baseline imbalances that suggest a problem with the 
randomization process?  
Probably No   
Risk of bias judgement Low  
   
Bias arising 
from the timing 
of identification 
and recruitment 
of individual 
participants in 
relation to 
timing of 
randomization 
 
1b.1 Were all the individual participants identified before randomization of 
clusters (and if the trial specifically recruited patients were they all recruited 
before randomization of clusters)? 
No Women were identified after randomization / 
intervention. Unlikely that individuals were 
recruited based on the knowledge of the 
intervention.  1b.2 If N/PN/NI to 1b.1: Is it likely that selection of individual participants was 
affected by knowledge of the intervention? 
Probably No 
1b.3 Were there baseline imbalances that suggest differential identification or 
recruitment of individual participants between arms? 
No Baseline characteristics balanced at study 
enrolment 
Risk of bias judgement Low  Low 
   
Bias due to 
deviations from 
intended 
interventions 
2.1a Were participants aware that they were in a trial? Yes Participants received a study flyer prior to being 
invited to participate and screening. Intervention 
was provided to clinic, not the participants. 
2.1b If Y/PY/NI to 2.1a: Were participants aware of their assigned intervention 
during the trial? 
Probably No  
2.2. Were carers and trial personnel aware of participants' assigned intervention 
during the trial? 
Yes Yes, intervention directed at the clinicians 
2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended 
intervention beyond what would be expected in usual practice? 
Probably No Unlikely as it was just an education and technical 
program on LARC specific issues.  
2.4. If Y/PY to 2.3: Were these deviations from intended intervention unbalanced 
between groups and likely to have affected the outcome? 
NA 
2.5a Were any clusters analysed in a group different from the one to which they 
were assigned? 
No ITT analysis 
2.5b Were any participants analysed in a group different from the one to which 
their original cluster was randomized? 
No ITT analysis 
2.6 If Y/PY/NI to 2.5: Was there potential for a substantial impact (on the 
estimated effect of intervention) of analysing participants in the wrong group? 
NA  
Risk of bias judgement Low  
   
 34 
Bias due to 
missing outcome 
data 
3.1a Were outcome data available for all, or nearly all, clusters randomized? Yes Data available for all clusters 
 
Control: 698 patients enrolled (78 excluded) > 
620 (89%) included in STI analysis (45 excluded) 
> 575 (82%) dual method use 
 
Intervention: 802 patients enrolled (66 excluded) 
> 736 (92%) included in STI analysis (64 
excluded) > (84%) 672 dual method use 
3.1b Were outcome data available for all, or nearly all, participants within 
clusters? 
  
3.2 If N/PN/NI to 3.1a or 3.1b: Are the proportions of missing outcome data and 
reasons for missing outcome data similar across intervention groups? 
NA  
3.3 If N/PN/NI to 3.1a or 3.1b: Is there evidence that results were robust to the 
presence of missing outcome data? 
NA  
Risk of bias judgement Low   
   
Bias in 
measurement of 
the outcome 
4.1a Were outcome assessors aware that a trial was taking place? Yes Outcome assessors were patients (self-report). No 
information on whether assessors of medical 
record data for STI knew status.  
4.1b If Y/PY/NI to 4.1: Were outcome assessors aware of the intervention 
received by study participants? 
 
NI 
No information.  
4.2 If Y/PY/NI to 4.1: Was the assessment of the outcome likely to be influenced 
by knowledge of intervention received? 
Probably No  
Risk of bias judgement Low Low for Dual Method / Some Concern for STI 
   
Bias in selection 
of the reported 
result 
Are the reported outcome data likely to have been selected, on the basis of the 
results, from... 
  
5.1. ... multiple outcome measurements (e.g. scales, definitions, time points) 
within the outcome domain? 
Probably No  
5.2 ... multiple analyses of the data? Probably No  
Risk of bias judgement Low  
   
Overall bias Risk of bias judgement Low  
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